Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-128727
Filing Date
2024-11-19
Accepted
2024-11-19 16:48:29
Documents
59
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q aktx-20240930.htm   iXBRL 10-Q 1933098
2 EX-31.1 aktx-ex31_1.htm EX-31.1 14979
3 EX-31.2 aktx-ex31_2.htm EX-31.2 14958
4 EX-32.1 aktx-ex32_1.htm EX-32.1 10756
5 EX-32.2 aktx-ex32_2.htm EX-32.2 10275
  Complete submission text file 0000950170-24-128727.txt   8540068

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT aktx-20240930.xsd EX-101.SCH 1490381
62 EXTRACTED XBRL INSTANCE DOCUMENT aktx-20240930_htm.xml XML 1405128
Mailing Address 22 BOSTON WHARF ROAD FL 7 BOSTON MA 02210
Business Address 22 BOSTON WHARF ROAD FL 7 BOSTON MA 02210 (646) 350-0702
Akari Therapeutics Plc (Filer) CIK: 0001541157 (see all company filings)

EIN.: 981034922 | State of Incorp.: X0
Type: 10-Q | Act: 34 | File No.: 001-36288 | Film No.: 241476936
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)